Cargando…

Two cases of type 2 diabetes mellitus in elderly patients successfully treated with monthly exenatide long‐acting release

Two elderly patients with poorly controlled type 2 diabetes mellitus had difficulty self‐managing their medications. Exenatide long‐acting release (LAR), with an extended administration interval of 1 month, maintained hemoglobin A1c (HbA1c) level in the 7% range. Monthly administration of exenatide‐...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takenaka, Kenchi, Nishitani, Rie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509896/ https://www.ncbi.nlm.nih.gov/pubmed/31110729 http://dx.doi.org/10.1002/ccr3.2139

Ejemplares similares

Long-acting preparations of exenatide
por: Cai, Yunpeng, et al.
Publicado: (2013)

Exenatide Microspheres for Monthly Controlled-Release Aided by Magnesium Hydroxide
por: Ge, Yuxuan, et al.
Publicado: (2021)

Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study
por: Davies, M J, et al.
Publicado: (2009)

Exenatide Use in the Management of Type 2 Diabetes Mellitus
por: Kyriacou, Angelos, et al.
Publicado: (2010)

Two-Layer Sustained-Release Microneedles Encapsulating Exenatide for Type 2 Diabetes Treatment
por: Liu, Han, et al.
Publicado: (2022)

Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications
por: Edwards, Krystal L., et al.
Publicado: (2006)

Effect of the Glucagon‐like Peptide‐1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus
por: Riederer, A., et al.
Publicado: (2016)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

Input Estimation for Extended-Release Formulations Exemplified with Exenatide
por: Trägårdh, Magnus, et al.
Publicado: (2017)

Exenatide-loaded inside-porous poly(lactic-co-glycolic acid) microspheres as a long-acting drug delivery system with improved release characteristics
por: Zhai, Junqiu, et al.
Publicado: (2020)

Long-Acting GLP-1 Receptor Agonist Exenatide Influence on the Autonomic Cardiac Sympatho-Vagal Balance
por: Cacciatori, Vittorio, et al.
Publicado: (2017)

Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
por: Watanabe, Yuusuke, et al.
Publicado: (2019)

Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide
por: Voukali, Maria, et al.
Publicado: (2014)

Determining Predictors of Early Response to Exenatide in Patients with Type 2 Diabetes Mellitus
por: Khan, Muhammad, et al.
Publicado: (2015)

Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus
por: Torimoto, Keiichi, et al.
Publicado: (2015)

Eosinophilic Panniculitis Following the Subcutaneous Injection of Exenatide Extended-Release
por: Ko, Jung-Woo, et al.
Publicado: (2020)

Glycemic variability in newly diagnosed diabetic cats treated with the glucagon‐like peptide‐1 analogue exenatide extended release
por: Krämer, Anna L., et al.
Publicado: (2020)

Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes
por: Sarkar, Gayatri, et al.
Publicado: (2014)

Exenatide Effects on Cardiometabolic Risk and Weight in Adolescents with Morbid Obesity and Type 2 Diabetes Mellitus: Two Case Reports
por: Censani, Marisa, et al.
Publicado: (2015)

Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
por: Mann, Katherine V, et al.
Publicado: (2014)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
por: Seewoodhary, Jason, et al.
Publicado: (2010)

Clinical experience with exenatide in obese North Indian patients with type 2 diabetes mellitus
por: Bawa, Tarunika, et al.
Publicado: (2013)

Hypoglycemia Abrogates the Vascular Endothelial Protective Effect of Exenatide in Type 2 Diabetes Mellitus
por: Torimoto, Keiichi, et al.
Publicado: (2019)

Exenatide extended-release; clinical trials, patient preference, and economic considerations
por: Doggrell, Sheila A
Publicado: (2013)

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
por: Henry, Robert R., et al.
Publicado: (2013)

The first successful desensitization protocol in exenatide allergy: a case report
por: Yeğit, Osman Ozan, et al.
Publicado: (2023)

Two cases of type 2 diabetes mellitus successfully treated with probiotics
por: Cardinali, Néstor, et al.
Publicado: (2020)

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus
por: Onishi, Yukiko, et al.
Publicado: (2012)

Evolution of Exenatide as a Diabetes Therapeutic
por: Bhavsar, Sunil, et al.
Publicado: (2013)

Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
por: Vetter, Marion L., et al.
Publicado: (2019)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study
por: Zhang, Xuesong, et al.
Publicado: (2016)

Persistent injection site nodules from exenatide: Successful treatment with intralesional triamcinolone
por: Riswold, Kayla, et al.
Publicado: (2018)

Association of Time in Range with Endothelial Injury in Patients with Type 2 Diabetes Treated with Exenatide
por: Le, Yunyi, et al.
Publicado: (2022)

Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus
por: Pereira, Marie, et al.
Publicado: (2017)

Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus
por: Guclu, Metin, et al.
Publicado: (2017)

Effects of PPARD gene variants on the therapeutic responses to exenatide in chinese patients with type 2 diabetes mellitus
por: Song, Jinfang, et al.
Publicado: (2022)

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
por: Simó, Rafael, et al.
Publicado: (2015)

No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks
por: Tatarkiewicz, K, et al.
Publicado: (2013)

Boerhaave syndrome in an elderly man successfully treated with 3-month indwelling esophageal stent
por: Y, Kopelman, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ljlp76jla3t90st2dickjn51ab